Crohn’s disease and transmural healing
Research activity in Crohn’s disease includes treatment strategies aimed at transmural response and deeper control of intestinal inflammation, with attention to endoscopic healing and disease activity in the small and large bowel.
- Transmural response
- Endoscopic healing
- Intestinal inflammation
The sponsor also supports work in patients with moderate to severe Crohn’s disease, reflecting a focus on active disease requiring advanced therapeutic management.
Postoperative Crohn’s disease and recurrence prevention
Another key area is postoperative recurrence after ileocolonic anastomosis, with interest in maintaining remission and preventing renewed mucosal injury following intestinal surgery.
- Postoperative recurrence
- Ileocolonic anastomosis
- Mucosal recurrence
Clinical research in this domain centers on patients with early postoperative lesions and the need for sustained control of Crohn’s disease activity.
Ulcerative colitis and treatment monitoring
The sponsor is also involved in ulcerative colitis, with studies examining treat-to-target care, patient education, and home-based monitoring tools to support tighter disease control during biologic treatment.
- Treat-to-target care
- Fecal calprotectin
- Telemonitoring
This area highlights interest in combining patient-reported follow-up with objective inflammatory markers to guide ongoing management in inflammatory bowel disease.
Perianal fistulising Crohn’s disease
Research also extends to fistulising perianal Crohn’s disease, a complex phenotype marked by active fistula tracts and significant therapeutic challenge within inflammatory bowel disease care.
- Perianal fistula
- Fistulising disease
- Complex Crohn’s phenotype
This focus reflects interest in difficult-to-treat disease manifestations that require specialized clinical attention.
Biologic therapy in inflammatory bowel disease
The sponsor’s trial portfolio includes evaluation of biologic therapies used in Crohn’s disease and ulcerative colitis, with attention to agents such as adalimumab, ustekinumab, guselkumab, and mirikizumab.
- Biologic treatment
- Advanced immunotherapy
- Inflammatory bowel disease
These studies place emphasis on therapeutic management across active intestinal inflammation, postoperative disease, and fistulising complications.
